{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.559","value":"-2.82"}]}],"title":"Week 24 (n = 1920)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.644","value":"-3.20"}]}],"title":"Week 48 (n = 1753)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.715","value":"-3.46"}]}],"title":"Week 96 (n = 1596)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.742","value":"-3.73"}]}],"title":"Week 264 (n = 1278)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \\[symptom-free and no arthritis symptoms\\], right end = maximum disease activity \\[maximum arthritis disease activity\\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"MEAN","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Change in the Disease Activity Score 28 (DAS-28) From Baseline to Weeks 24, 48, 96, and 264","type":"SECONDARY","unitOfMeasure":"Units on a scale"}